Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: A dose-conversion and titration study

International Journal of Clinical Practice

Volumn 61, Issue 10, 2007, Pages 1671-1676

  Wallace, M ^a   Rauck, R L ^b   Moulin, D ^c   Thipphawong, J ^d   Khanna, S ^d   Tudor, I C ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; OPIATE AGONIST; OROS; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG STABILITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SOMNOLENCE; SWEATING; VOMITING; XEROSTOMIA;

ADULT; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; QUESTIONNAIRES; TITRIMETRY; TREATMENT OUTCOME;

EID: 34548614385     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01500.x     Document Type: Article

References (20)

1. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000 17 : 70 83.
2. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain 2005 9 : 127 30.
3. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002 1, CD003447. DOI:.
4. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001 9 : 84 96.
5. Vallner JJ, Stewart JT, Kotzan JA et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981 21 : 152 56.
6. Ferrell B, Wisdom C, Wenzl C et al. Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 1989 16 : 521 26.
7. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001 8 : 181 86.
8. Drover DR, Angst MS, Valle M et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002 97 : 827 36.
9. Palangio M, Northfelt DW, Portenoy RK et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002 23 : 355 68.
10. Storey P, Hill HH Jr., St Louis RH et al. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 1990 5 : 33 41.
11. Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996 78 : 852 57.
12. Lawlor P, Turner K, Hanson J et al. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997 72 : 79 85.
13. Storey P. More on the conversion of transdermal fentanyl to morphine. J Pain Symptom Manage 1995 10 : 581 82.
14. Shah J, Gupta S, Singh S et al. Multiple dose pharmacokinetics of OROS and immediate release (IR) hydromorphone (HM) in healthy subjects [abstract]. Pharm Res 1997 14 : S617.
15. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983 17 : 197 210.
16. Sittig HB. Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study. MMW Fortschr Med 2004 146 (Suppl. 3-4 95 8.
17. Deschamps M, Band PR, Hislop TG et al. The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. J Pain Symptom Manage 1992 7 : 384 92.
18. Salzman RT, Roberts MS, Wild J et al. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control J Pain Symptom Manage 1999 18 : 271 79.
19. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th edn. Glenview, IL : American Pain Society, 2003.
20. Weinstein SM, Shi M, Buckley BJ et al. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clin Ther 2006 28 : 86 98.